Well, I think for XCHO (Xena Care), the 10-Q will answer our questions. XCHO's revenue numbers are the ones that should be used to measure Cobroxin sales, not those of NPHC (Nutra Pharma).
It seems that NPHC made overly optimistic projections and that recent PR release was a way for them to save face with their investors. It is way too early to predict XCHO's end result.
I believe XCHO is doing a good job so far based on everything I research. Everyone knew Xenacare's limited budget and should have expected a gradual increase in advertising for the first year. Everyone knew this apparently, but NPHC. We will see.
News 
Market Data 
Discover 
AI
